logo
Your Cancer monthly horoscope for August 2025

Your Cancer monthly horoscope for August 2025

Cosmopolitana day ago
You are focused on your sense of security, Cancer! The month starts off in Leo season, which brings attention to your resources and professional life. Are you being paid your worth? It might be time to ask for a raise or find a new position at a job that truly values you. This can also be a busy time for making upgrades in your world - making important purchases and getting back on track with your budget. You are also spending more time getting crystal clear on your personal values systems, and ready to embody what you believe.
Your personal life is full of strife when Mars moves into Libra on 6 August. You might need to set boundaries with a roommate or family member. Perhaps a loved one is moving through a challenging situation and relying on you more for support. This can also be a busy time at home - maybe you're moving or changing up your living space in some way.
You might feel torn between your longterm goals and the past when Mars in Libra faces off with Saturn in Aries on 8 August. You could encounter a temporary setback or receive disappointing news at work or regarding a loved one. You might also feel ready to move on from the past or set a firm boundary with a toxic boss or co-worker.
The Full Moon in Aquarius on 9 August brings your deeper feelings to the surface. You're feeling raw and opening up to loved ones. This energy can be both triggering and healing. Practically, this marks a shift in your financial situation. Maybe a contract wraps up, you're paying down some debt, or you have to rework your budget.
Fortunately, financial matters begin to clear up the following day, on 11 August, when Mercury retrograde in Leo ends. Conversations about a raise that were delayed pick up once again. You might also hear back from a job you applied to or feel confident enough to ask for a raise. Luck is on your side on the same day when Venus and Jupiter, the two most fortunate planets in the sky, share a kiss - in your sign! You are the main character and can use this energy however you see fit. You're feeling grateful and excited about what comes next - whether it's regarding love, friendship, personal goals, or professional milestones. Take a risk today because the Universe is on your side.
Conversations with loved ones feel grounding and it's easy to clear the air when Mercury in Leo syncs up with Mars in Libra on 14 August. You could also learn news about your work situation that brings more financial stability or boosts your confidence in your own gifts or talents. Thoughtful gifts are exchanged.
The Sun enters Virgo on 22 August, and you're more focused on your mindset. The next few weeks help you shift your own limiting beliefs. New, important conversations emerge and you're also full of ideas. There's a New Moon in Virgo, on the same day, that invites you to learn something new. Maybe you start learning a new hobby or a new language. You could also book travel or learn something important about a BFF, sibling, or family member. These relationships can shift and experience renewal.
Positive financial news arrives once Venus moves into Leo on 25 August. The next few weeks bring financial opportunities your way or help you get back on track with your budget. You could also invest in a new wardrobe and find yourself donating old items and thrifting new ones. First, you'll have to address power struggles and uncomfortable topics regarding finances - especially in your close relationships - when Venus in Leo faces off with Pluto in Aquarius on 26 August. You might need to ask for help or set a boundary with a roommate who's been taking advantage of your generosity.
The month wraps up with supportive and surprising developments on your life path when Uranus in Gemini teams up with Neptune in Aries on 28 August. You are feeling divinely guided and protected. Listen to your intuition when making decisions about your future today.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bet365 Bonus Code WEEK365: Claim $150 Bonus For 15 Sunday MLB Games
Bet365 Bonus Code WEEK365: Claim $150 Bonus For 15 Sunday MLB Games

Newsweek

time4 hours ago

  • Newsweek

Bet365 Bonus Code WEEK365: Claim $150 Bonus For 15 Sunday MLB Games

The bet365 bonus code WEEK365 will give new users a $150 bonus to use on a full slate of Sunday MLB games, including Mets vs. Giants in primetime. The bet365 bonus code WEEK365 will give new users a $150 bonus to use on a full slate of Sunday MLB games, including Mets vs. Giants in primetime. Create a new sportsbook account with the bet365 bonus code WEEK365 to secure a $150 bonus offer or a $1,000 first bet safety net. Use the promo of your choice to bet on MLB games, WNBA games or the final round of the 3M Open. Click here to start the registration process. All it takes to activate the $150 bonus offer is a $5 bet on any game. The $1,000 first bet safety net give you the flexibility to wager up to that amount. A losing wager will trigger a bonus refund equal to the stake you wagered. There are plenty of betting opportunities to cash in on with these promos on Sunday. A full MLB slate is headlined by matchups like Blue Jays-Tigers, Phillies-Yankees and Dodgers-Red Sox. There are also five WNBA games to bet on, including Mercury-Mystics and Dream-Lynx. The 3M Open will also qualify for these offers. How To Use bet365 Bonus Code WEEK365 Offers Bet365 Bonus Code WEEK365 New User Offer Bet $5, get $150 Bonus OR $1,000 first bet safety net In-App Promos MLB 30% SGP Boost, MLB Instant Payout, MLB Daily Lineups, etc. Terms and Conditions New Customers - 21+ in Eligible States Bonus Last Verified On July 27, 2025 Information Confirmed By Newsweek The $1,000 first bet safety net is simple to use, so let's go through that one first. As noted above, you can bet up to that amount and get your stake back if your bet loses. As an example, if you bet something like $600 on the Tigers to beat the Blue Jays, you will get a large payout to jumpstart your account if your bet wins. If your bet loses, you will get your $600 stake refunded in the form of a bonus. A bet on any other market across bet365 will work the same way with this offer. If you prefer the $150 bonus offer, you just have to place a $5 bet on any market. The outcome of that bet does not matter, and you will get the bonus bets credited to your account before your initial bet even settles. For example, if you bet $5 on one of the MLB games, you will instantly secure your $150 in bonus bets. MLB Boosts For July 27 Games When you are set up with a new bet365 account, you will have the opportunity to take advantage of markets with boosted odds. Go to a specific sport that interests you to survey the popular pre-made parlay options with boosted odds. If you click on an individual game, you will be able to find the popular boosted parlays for that specific event. These markets could be good to target with any bonus bets you receive with one of the welcome promos. How To Sign Up With bet365 Bonus Code WEEK365 Start the registration process by clicking here. Enter the bonus code WEEK365 and provide basic personal information, like your name, date of birth, mailing address, email address, etc. to secure your new account. The next step is to make an initial deposit that will cover your first wager with bet365. This can be completed with a credit card, debit card, PayPal account or several other secure payment options. The last step is to place your first wager to activate your desired welcome offer. Any bonus bets you receive will be valid for seven days before they expire. Newsweek may earn an affiliate commission if you sign up through the links in this article. See the sportsbook operator's terms and conditions for important details. Sports betting operators have no influence over newsroom coverage.

BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra
BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra

Yahoo

time11 hours ago

  • Yahoo

BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra

We recently compiled a list of BeOne Medicines Ltd. stands ninth on our list. BeOne Medicines Ltd. (NASDAQ:ONC), formerly BeiGene, is a global oncology company now headquartered in Switzerland following its May 2025 redomiciliation. The strategic move enhances the company's access to European biotech networks and regulatory alignment, supporting its mission to lead in cancer innovation. With operations in over 45 countries and a pipeline of 50+ investigational assets, the business is rapidly expanding its R&D and clinical presence. A major milestone for BeOne Medicines Ltd. (NASDAQ:ONC) this year was the European Commission's approval of Tevimbra (tislelizumab) for multiple indications, including extensive-stage small cell lung cancer and nasopharyngeal carcinoma, further cementing its role in immuno-oncology. Tevimbra is already FDA-approved for esophageal cancer, and continued regulatory momentum is expected. In hematology, the corporation showcased significant advances at the 2025 EHA Congress. Sonrotoclax (a BCL2 inhibitor) and BGB-16673 (a first-in-class BTK degrader) delivered promising results in treating resistant forms of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), advancing toward Phase 3 trials. Meanwhile, BRUKINSA (zanubrutinib) remains a core therapy, demonstrating superior outcomes compared to ibrutinib. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. BeOne Medicines Ltd. (NASDAQ:ONC) also made strides in pipeline growth, advancing 13 new molecules into clinical trials in 2024 alone. With 170+ global trials and over 25,000 patients enrolled, its 'Fast to Proof-of-Concept' strategy accelerates timelines and patient access. In June 2025, a licensing deal with Neowise Biotechnology expanded the business's efforts in next-gen cell therapies, particularly TCR-based platforms.\ While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth

Yahoo

time12 hours ago

  • Yahoo

Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Genmab A/S stands eighth on our list and has recently opened new sites in the US. Genmab A/S (NASDAQ:GMAB), a Danish biotech company founded in 1999, specializes in antibody-based therapies for cancer and serious diseases. Known for its technologies like HuMab-Mouse and UniBody, the corporation has historically partnered with major pharmaceutical companies such as Johnson & Johnson and AbbVie to bring its innovations to market. However, the company is now undergoing a strategic transformation to become a fully integrated global commercial entity. In June 2025, Genmab A/S (NASDAQ:GMAB) opened a major new U.S. site in Plainsboro, New Jersey, signaling a shift from a partnership-driven model to direct commercialization of its therapies. This move gives the company greater control over its innovation, regulatory processes, and patient outreach, aligning with a broader biotech industry trend toward independence and vertical integration. The business's oncology portfolio continues to gain traction. Tivdak (cervical cancer) received full FDA approval in April 2024, while Epkinly (lymphoma), which earned accelerated approval in 2023, has shown strong sales growth in the U.S. Genmab A/S (NASDAQ:GMAB)'s pipeline also remains active, with ongoing development of therapies like Epcoritamab and Acasunlimab. At the June 2025 ASCO meeting, the company presented promising Rina-S data, supporting an upcoming Phase III trial. A healthcare professional wearing a health communications device discussing patient data with a colleague. The corporation continues to benefit from its successful collaboration with Johnson & Johnson on DARZALEX, which remains a significant revenue driver. The company is also focused on long-term growth by investing in talent retention through stock-based incentives. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store